Gilead Sciences, Inc. (GILD) stock moves up, “Buy” rating reaffirmed by Citigroup Inc. Analysts

Gilead Sciences, Inc. (NASDAQ: GILD) shares rose on Wednesday January 25 on lower trade volume than normal after a number of analysts weighed in on the investing value of the stock and reiterated thier respective ratings.

Meanwhile, the Dow Jones Industrial Average on Wednesday crossed the 20,000 level for the first time, while the S&P 500 and Nasdaq Composite also traded in record territory shortly after the market opened

The Dow Jones Industrial Average DJIA, +0.60% advanced 100 points, or 0.5%, to 20,012,
The S&P 500 index SPX, +0.55% gained 10 points, or 0.5%, to 2,289, with eight of the main 11 sectors trading higher.

The Nasdaq Composite index COMP, +0.66% was 30 points, or 0.6%, higher at 5,630.

All three main indexes set intraday records shortly after the opening bell.

Gilead Sciences, Inc. (NASDAQ: GILD) had its Buy rating reiterated by equities researchers at Citigroup Inc. in a research note to investors. With a rating of Buy on the stock, Gilead Sciences, Inc. has a 52-week high of $103.10. As a means of comparison, a number of other analysts have commented on the stock in recent days, and Gilead Sciences, Inc. has earned a consensus one-year price target of $95.10, above the opening price of $70.82, a difference of 13.28 percent. Usually, after analysts issue a “reiterated rating” report on a stock, they will subsequently issue sporadic revisions, often followed by a price target change.

Shares of Gilead Sciences, Inc. (NASDAQ: GILD) opened at $70.82 yesterday trading between $70.72 and $71.75, and last traded at $71.60, a jump of $1.35 compared to the previous closing price.

Gilead Sciences, Inc. (NASDAQ: GILD) now has a market cap of 94.33B.

Gilead Sciences, Inc. (NASDAQ: GILD) Average Daily Trading Volume

The stock’s average daily volume is 9,842,880 shares out of a total float 1,308,378,000 and some 2,268,885 shares traded hands yesterday, 27 percent lower than the norm. lower than normal. Look for trading volume to pick up in the coming days as momentum traders often use increases in trading volume to identify heavy volume accumulation or distribution by institutional investors.

However, a single day of heavy buy side trading is not enough to assert a trend. As such, market traders will continue to watch for institutional sponsorship as a signal that financial institutions are moving forward.

Institutional sponsorship is defined by ownership of a stock by mutual funds, banks, pension funds and other large institutions.

Professional investors such as these have substantial teams of analysts that research thousands of stocks. Thus, watching their interests is a good way to ensure you are buying the right stocks.

Gilead Sciences, Inc. (NASDAQ: GILD) Moving Averages

A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.

This is because the average acts like a floor (support), so the price bounces up off of it.

In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.

By spotting trends, moving averages allow investors to make those trends work in their favor and increase the number of successful trades.

Trades for Gilead Sciences, Inc. (NASDAQ: GILD) have ranged from $69.78 – 103.10, and the stock now has a 50-day MA of $73.45 and 200-day MA of $77.05. Today’s last price is 30.55%% under the 52 week high of $103.10.

Earnings growth is a critical factor to look at when buying stocks and investors seek companies that have grown their earnings at least 25% or more for a 3 year period.

DISCLOSURE: The views and opinions expressed in this article do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Latest News

Leave a Reply